Gregory M LaMonte, Elizabeth A Winzeler, Yo Suzuki, Rommie E Amaro, Carolyn W Slayman, Case W McNamara, Maximo Prescott, Rebecca Murray, Marie Nachon, Ayako Murao, Micah J Manary, Gregory M Goldgof, Jake Schenken, Jennifer Yang, Kiersten A Henderson, Maxim Kostylev, Felicia Gunawan, Kenneth E Allen, Edgar Vigil, Sabine Ottilie, Jacob D Durrant
Journal: Scientific reports 2018;6():27806
PMID: 27291296
The spiroindolones, a new class of antimalarial medicines discovered in a cellular screen, are rendered less active by mutations in a parasite P-type ATPase, PfATP4. We show here that S. cerevisiae also acquires mutations in a gene encoding a P-type ATPase (ScPMA1) after exposure to spiroindolones and that these mutations are sufficient for resistance. KAE609 resistance mutations in ScPMA1 do not confer resistance to unrelated antimicrobials, but do confer cross sensitivity to the alkyl-lysophospholipid edelfosine, which is known to displace ScPma1p from the plasma membrane. Using an in vitro cell-free assay, we demonstrate that KAE609 directly inhibits ScPma1p ATPase activity. KAE609 also increases cytoplasmic hydrogen ion concentrations in yeast cells. Computer docking into a ScPma1p homology model identifies a binding mode that supports genetic resistance determinants and in vitro experimental structure-activity relationships in both P. falciparum and S. cerevisiae. This model also suggests a shared binding site with the dihydroisoquinolones antimalarials. Our data support a model in which KAE609 exerts its antimalarial activity by directly interfering with P-type ATPase activity.
Full Text Sources:
Other Literature Sources:
Molecular Biology Databases:
© Copyright 2026, Nutrition Evidence
We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.